Search Results - "Fasola, G."

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection by Schirripa, M, Bergamo, F, Cremolini, C, Casagrande, M, Lonardi, S, Aprile, G, Yang, D, Marmorino, F, Pasquini, G, Sensi, E, Lupi, C, De Maglio, G, Borrelli, N, Pizzolitto, S, Fasola, G, Bertorelle, R, Rugge, M, Fontanini, G, Zagonel, V, Loupakis, F, Falcone, A

“…Background: Despite major advances in the management of metastatic colorectal cancer (mCRC) with liver-only involvement, relapse rates are high and reliable…”
Get full text

Pattern of metastasis and outcome in patients with breast cancer by Gerratana, L., Fanotto, V., Bonotto, M., Bolzonello, S., Minisini, A. M., Fasola, G., Puglisi, F.

“…There is growing evidence about differences in metastatic spread among breast cancer (BC) biologic subtypes (BS). Aim of this study was to analyze the pattern…”
Get full text

Analysis of workload generated in the two years following first consultation by each new cancer patient: studying the past to plan the future of cancer care by Garattini, S K, Valent, F, Minisini, A M, Riosa, C, Favaretti, C, Regattin, L, Fasola, G

“…Prevalence of cancer patients is dramatically increasing. We aimed at quantifying the oncology workload generated by each new cancer patient in the two years…”
Get full text

Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer by Fornaro, L, Cereda, S, Aprile, G, Di Girolamo, S, Santini, D, Silvestris, N, Lonardi, S, Leone, F, Milella, M, Vivaldi, C, Belli, C, Bergamo, F, Lutrino, S E, Filippi, R, Russano, M, Vaccaro, V, Brunetti, A E, Rotella, V, Falcone, A, Barbera, M A, Corbelli, J, Fasola, G, Aglietta, M, Zagonel, V, Reni, M, Vasile, E, Brandi, G

“…Background: The role of second-line chemotherapy (CT) is not established in advanced biliary tract cancer (aBTC). We investigated the outcome of aBTC patients…”
Get full text

What to do in an oncology department to face the new COVID-19 era challenges? by Garattini, S. K., Bin, A., Donato, R., Mansutti, M., Rizzato, S., Troiero, G., Candoni, A., Fanin, R., Fasola, G.

“…Italy was the first European country to be hit by COVID-19 pandemic. As a consequence, Italian oncologists had to guarantee essential treatments although…”
Get full text

KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic non-squamous NSCLC by Cinausero, M., Laprovitera, N., De Maglio, G., Gerratana, L., Riefolo, M., Macerelli, M., Fiorentino, M., Porcellini, E., Buoro, V., Gelsomino, F., Squadrilli, A., Fasola, G., Tiseo, M., Ferracin, M., Ardizzoni, A.

Get full text

Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian Epidemiological study: THE NET MANAGEMENT STUDY by Faggiano, A., Ferolla, P., Grimaldi, F., Campana, D., Manzoni, M., Davì, M. V., Bianchi, A., Valcavi, R., Papini, E., Giuffrida, D., Ferone, D., Fanciulli, G., Arnaldi, G., Franchi, G. M., Francia, G., Fasola, G., Crinò, L., Pontecorvi, A., Tomassetti, P., Colao, A.

“…Background: The few epidemiological data available in literature on neuroendocrine tumors (NET) are mainly based on Registry databases, missing therefore…”
Get full text

Serum markers as predictors of immune checkpoint inhibitors (ICI) related adverse events in a real-world scenario by Iacono, D., Vitale, M.G., Cortiula, F., Cinausero, M., Tullio, A., Valent, F., Macerelli, M., Follador, A., Vogrig, A., Minisini, A.M., Puglisi, F., Fasola, G.

Get full text

Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study by Roila, F., Ruggeri, B., Ballatori, E., Fatigoni, S., Caserta, C., Licitra, L., Mirabile, A., Ionta, M.T., Massidda, B., Cavanna, L., Palladino, M.A., Tocci, A., Fava, S., Colantonio, I., Angelelli, L., Ciuffreda, L., Fasola, G., Zerilli, F.

“…A combination of aprepitant, a 5-HT3 receptor antagonist (r.a.), and dexamethasone is recommended for the prophylaxis of cisplatin-induced nausea and vomiting…”
Get full text

Expression of periostin in human breast cancer by Puglisi, F, Puppin, C, Pegolo, E, Andreetta, C, Pascoletti, G, D'Aurizio, F, Pandolfi, M, Fasola, G, Piga, A, Damante, G, Di Loreto, C

“…Periostin is a secreted adhesion protein, normally expressed in mesenchime-derived cells. Aberrant expression of the periostin gene in epithelial tumours seems…”
Get more information

Clinical features of never smoker patients with lung squamous cell carcinoma: a retrospective multicenter study by Frega, S., Macerelli, M., Del Conte, A., Bonanno, L., Bartoletti, M., Polo, V., Zago, G., Follador, A., Attili, I., Pavan, A., Urso, L., Basso, S.M.M., Fasola, G., Conte, P., Pasello, G.

Get full text

Predicting HER2 status in esophagogastric cancer: Development and validation of an easy-to-use nomogram by Fornaro, L., Parnofiello, A., Ugolini, C., Cardarelli, N., De Maglio, G., Pecora, I., Crivelli, F., Catanese, S., Cardellino, G., Musettini, G., Pella, N., Pasquini, G., Pizzolitto, S., Salani, F., Clerico, M., Fontanini, G., Fasola, G., Maurizio, D., Vivaldi, C., Montagnani, F.

Get full text

Time to surgery after neoadjuvant chemotherapy for early breast cancer by Cinausero, M, Galli, G, Basile, D, Gerratana, L, Fasola, G, De Braud, F, Sant, M, Paolini, B, Puglisi, F, Di Cosimo, S

Get full text

Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma by Iacono, D., Basile, D., Gerratana, L., Vitale, M.G., Pelizzari, G., Cinausero, M., Poletto, E., Puglisi, F., Fasola, G., Minisini, A.M.

Get full text

First-line platinum-based chemotherapy in elderly patients with NSCLC: determinants of therapeutic choice and outcome by Pelizzari, G., Gerratana, L., Cattaneo, M., Cortiula, F., Lisanti, C., Bartoletti, M., Giavarra, M., Buoro, V., De Carlo, E., Macerelli, M., Poletto, E., Rossetto, C., Rizzato, S., Puglisi, F., Fasola, G.

Get full text

How can molecular heterogeneity impact on treatment choice in advanced colorectal cancer? by De Maglio, G., Ongaro, E., Pella, N., Ciani, S., Cernic, S., Giovannoni, M., Ermacora, P., Cardellino, G.G., Iacono, D., Aprile, G., Pizzolitto, S., Fasola, G.

Get full text

Transformation of Cancer Care during and after the COVID Pandemic, a point of no return. The Experience of Italy by Tarricone, R., Listorti, E., Tozzi, V., Torbica, A., Banks, H., Ghislandi, S., Altini, M., Annicchiarico, M., Ardizzoni, A., Bordon, P., Bossi, P., Cascinu, S., Numico, G., Puglisi, F., Fasola, G.

“…•Cancer care planning and delivery must take a comprehensive, nationwide approach to guarantee access to innovation.•Digital, community and primary care…”
Get full text

Risk factors and survival outcomes in patients with brain metastases from breast cancer by Minisini, A. M., Moroso, S., Gerratana, L., Giangreco, M., Iacono, D., Poletto, E., Guardascione, M., Fontanella, C., Fasola, G., Puglisi, F.

“…Development of central nervous system (CNS) metastases in breast cancer (BC) is associated with poor prognosis. The incidence of CNS metastases in metastatic…”
Get full text

The SENECA study: Prognostic role of serum biomarkers in elderly metastatic colorectal cancer patients by Lisanti, C., Basile, D., Garattini, S.K., Pelizzari, G., Parnofiello, A., Cortiula, F., Ongaro, E., Cattaneo, M., Corvaja, C., Andreotti, V.J., Bartoletti, M., Casagrande, M., Iacono, D., Bonotto, M., Ermacora, P., Pella, N., Buonadonna, A., Puglisi, F., Fasola, G., Miolo, G.

Get full text

A risk score integrating lymphocytes ratios (LRs) and lactate dehydrogenase (LDH) levels to predict prognosis in metastatic breast cancer (MBC) patients by Pelizzari, G., Gerratana, L., Basile, D., Zago, S., Vitale, M.G., Bartoletti, M., Lisanti, C., Fanotto, V., Corvaja, C., Bortot, L., Liguori, A., Cinausero, M., Russo, S., Andreetta, C., Bonotto, M., Mansutti, M., Minisini, A.M., Curcio, F., Fasola, G., Puglisi, F.

Get full text